N
atural killer (NK) cells are effector cells of the innate immune system that exhibit direct cytotoxic function (1, 2) . NK cell activation is determined by a delicate balance of signals delivered by inhibitory and activating receptors (1) (2) (3) . Inhibitory receptors bind to MHC class I molecules and down-regulate NK cell cytotoxicity and cytokine production. Thus, missing or low self-MHC expression activates NK cells and initiates target cell lysis (2, 3) . Activating receptors are Ig-like or lectin-like molecules that initiate signaling cascades similar to those in T cells. Signaling through activating receptors can overcome inhibitory signaling when the ligands for activating receptors are abundant (3) .
Recent studies have revealed that NK cells interact with dendritic cells (DC) (4, 5) and that this interaction can mediate cytotoxic T cell differentiation and NK cell activation/priming (6) . For instance, DC-mediated NK cell activation is crucial for antiviral immunity (5) . However, the underlying molecular and cellular mechanisms to control DC-mediated NK cell activation are poorly understood.
Notch is a transmembrane receptor activated by the interaction with Notch ligands. Mammals possess four Notch receptors and five Notch ligands. Notch ligands are categorized by two families, Delta (1, 3, and 4) and Jagged (1 and 2) (7) . The interaction between a ligand-receptor pair cleaves the extracellular and transmembrane domains of Notch, resulting in the translocation of the intracellular domain of Notch to the nucleus. The interaction of the intracellular domain of Notch with RBP-J allows the formation of transcriptional DNAprotein complexes, leading to specific gene expression. Notch signaling generally controls cell fate choice, cell survival, and activation in many cell types. Recent studies have demonstrated that Notch signaling controls both the development and activation of T cells (7) (8) (9) (10) . Furthermore, two papers reported that stimulation of hematopoietic stem cells by Jagged1 or Jagged2 promotes NK cell differentiation (11) (12) . However, whether Jagged controls mature NK cell activation or functional differentiation in vivo requires further investigation.
In this report, we addressed whether or not one of the Notch ligands, Jagged2, controls NK cell responses in vivo. We found that stimulation of NK cells by Jagged2 enhanced the antitumor cytolytic activity of NK cells in vivo and in vitro. In addition, Jagged2 expressed on DC augmented NK cell function through interaction with Notch. These results suggest that robust Notch signaling by enhanced Jagged2 expression may provide a useful strategy to eradicate tumor cells. Conversely, the inhibition of Jagged2-Notch interaction might help cure certain autoimmune diseases caused by the overactivation of NK cells.
Results
Overexpression of Jagged2 on A20 Cells Accelerated A20 Rejection in BALB/c Mice. We first investigated the role of Jagged2 in NK cell activation by overexpressing Jagged2 on A20 cells. A20 is a BALB/c-derived B cell lymphoma cell line that expresses high levels of MHC class II, low levels of MHC class I, Jagged1 and Delta1, and no Jagged2 or Delta4 (Fig. 1a) . We transfected Jagged2 (Jag2-A20 cells) or a control vector (c-A20 cells) into A20 cells, and Ϸ75% of Jag2-A20 cells expressed Jagged2 after zeocin selection (Fig. 1b) . The expression levels of NKG2D ligands and MHC class I on Jag2-A20 cells were comparable with those of c-A20 cells (Fig. 1c) .
To examine the effect of Jagged2 on antitumor immunity, both cell lines were inoculated s.c. in naïve BALB/c mice, and tumor sizes were monitored (Fig. 1d) . The growth of c-A20 cells was detectable 19 days after inoculation, and c-A20 cells continued to grow in BALB/c mice (Fig. 1d) . In contrast, Jag2-A20 cells were detectable 28 days after inoculation, and the growth of tumors was greatly suppressed compared with that of c-A20 cells (Fig. 1d) . NK cells infiltrated more in Jag2-A20 than c-A20 tumors at 10 days after inoculation [supporting information (SI) Fig. S1 ]. These results suggest that overexpression of Jagged2 on A20 cells enhances the immune-mediated rejection of A20 cells.
To rule out the possibility that Jag2-A20 cells have acquired an intrinsic slow-proliferation phenotype, we compared the proliferation of Jag2-A20 cells and c-A20 cells in vitro. [ 3 H]thymidine incorporation was quite similar in both cell lines under three different cell concentration conditions (Fig. 1e) . Taken together, these results eliminated the possibility that the overexpressed Jagged2 directly slowed down the proliferation of A20 cells, suggesting that the retarded growth of Jag2-A20 in mice might be a consequence of augmented immune surveillance.
Growth of Jag2-A20 Cells Is Suppressed Even in SCID Mice, and NK Cells Are Involved in Jagged2-Mediated Tumor Suppression. We next examined whether mature T or B cells caused the reduced growth of Jag2-A20 cells by inoculating Jag2-A20 cells into T cell-and B cell-deficient SCID mice. The c-A20 cells grew in SCID mice similarly in BALB/c mice (Fig. 2a) . In contrast, the Jag2-A20 tumor size was much smaller in SCID mice compared with that of c-A20 cells, which indicates that T and B cells are not major players in suppressing the growth of Jag2-A20 cells (Fig. 2a) . Collectively, these results suggest a role for NK cells in suppressing Jag2-A20 tumor growth. Thus, we next examined the tumor growth of Jag2-A20 cells in NK-depleted SCID mice that had been treated with anti-asialo-GM1 mAb (Fig. 2b) . In fact, this treatment specifically restored the in vivo growth of Jag2-A20 cells (Fig. 2b) . It is of note that the depletion of NK cells augmented the tumor growth of c-A20 cells in SCID mice, indicating that NK activation occurred to a moderate degree upon inoculation of c-A20 cells, although the activation was not strong enough to reject A20 cells. Additionally, the c-A20 tumor size was larger than that of Jag2-A20 after NK cell depletion (Fig. 2b) , suggesting the presence of an NK cellindependent aspect of the Jagged2-mediated suppression in this context. Taken together, these results suggest that the overexpression of Jagged2 on A20 cells enhanced the antitumor response of NK cells against A20 cells.
Enhanced Cytotoxic Activity of NK Cells from BALB/c Mice Inoculated with Jag2-A20 Cells. To confirm that the enhanced tumor suppression of Jag2-A20 cells ref lected augmented cytotoxicity of NK cells, we purified NK cells from the spleens of c-A20-or Jag2-A20-inoculated BALB/c mice and examined them in an in vitro killing assay. The cytotoxic activity against A20 cells was markedly elevated in NK cells harvested from Jag2-A20-inoculated BALB/c mice compared with those from c-A20-inoculated or untreated mice (Fig. 3a) . Therefore, these results indicate that overexpression of Jagged2 in A20 cells enhanced the killing activity of NK cells in vivo. between anti-asialo-GM1-treated and control rabbit antibody-treated Jag2-A20-inoculated mice or between anti-asialo-GM1-treated and control rabbit antibody-treated c-A20-inoculated mice. These results are representatives of four independent experiments.
We next tested whether Jagged2 augments the proliferation, IFN-␥ production and expression of effector molecules by NK cells. We isolated DX5 ϩ NK cells from BALB/c mice and incubated them with YAC-1 cells transfected with a control vector or a Jagged2-encoding vector (Fig. 3b) , with c-A20 or Jag2-A20 cells (Fig. 3c) , or with OP9 cells transfected with a control vector or a Jagged2-encoding vector (Fig. 3d) . The presence of Jagged2 on YAC-1, A20, or OP9 cells apparently enhanced the proliferation, IFN-␥ secretion, or granzyme B transcription of NK cells, respectively (Fig. 3  b, c, and d ). These results demonstrate that Jagged2 enhances NK cell functions, including cytotoxicity, proliferation and IFN-␥ production.
Inoculation of Jag2-A20 Cells Enhanced the Antitumor Effect of NK
Cells to Kill A20 Cells Transplanted at a Different Site. We then postulated that the exposure of NK cells to Jagged2-expressing cells could condition them to become activated killers, and these cells could subsequently eradicate bystander tumor cells that are defective for Jagged2 expression. To this end, we inoculated Jag2-A20 and A20 cells or c-A20 and A20 cells at different sites on the same SCID mouse and monitored the tumor size of the bystander A20 cells (Fig. 4a) . The growth of A20 cells in SCID mice inoculated bilaterally with Jag2-A20 cells was suppressed compared with that of mice that received c-A20 cells (Fig. 4a) . This effect of Jag2-A20 cells was diminished by treating SCID mice with anti-asialo-GM1 mAb, indicating that NK cells are responsible for this effect (Fig. 4b) .
Transfection of Jagged2 in tumor cells is not a favorable clinical method to accomplish enhanced NK cell activity. Thus, we examined whether DC overexpressing Jagged2 (Jag2-DC) are able to augment NK cell activity. Jagged2 was transduced into bone marrow-derived DC by a retroviral vector. Then Jag2-DCs or control virus-transduced DC (c-DC) were coinjected with A20 cells, and the tumor size was monitored. The inoculation of Jag2-DC significantly suppressed the growth of A20 cells compared with c-DC (Fig. 4c) . This result indicates the feasibility for the use of DC as a vehicle to enable Jagged2-mediated augmentation of NK cell activity in vivo, and opens up the possibility for therapeutic tumor intervention. Jagged2 on DC Directly Activates NK Cells. To explore the physiological roles of Jagged2 in terms of NK cell activation, we examined whether Jagged2 is involved in DC-mediated NK cell activation. We first analyzed Jagged2 expression on splenic DC. Splenic DC from untreated BALB/c mice express little Jagged2, and CpG-administration to mice up-regulated Jagged2 expression on DC (Fig. 5a) . Furthermore, the expression of Jagged2 on DC was limited to the CD8␣ ϩ subset. Bone marrow-derived DC cultured in the presence of GM-CSF express Jagged2 (Fig. 5b) . CpG stimulation of bone marrow-derived DC up-regulated Jagged2 expression, although the level was lower than that of DC transduced with a Jagged2-expressing retrovirus (Fig. 5b) . CpG stimulation of bone marrow-derived DC also up-regulated expression of Delta1 and Jagged1 but not Delta4, compared with controls (Fig. S2) .
To test whether Jagged2 expressed on DC is able to directly activate NK cells, we examined NK cell cytotoxic activity after coculture with Jag2-DC. The coculture of Jag2-DC and NK cells increased the cytotoxic activity of NK cells over that of unstimulated NK cells (Fig. 5c) . We examined whether blocking Notch signaling decreases DC-mediated NK cell cytotoxicity by treating NK cells with a ␥-secretase inhibitor (GSI). GSI treatment inhibited NK cell activation mediated by Jag2-DC (Fig. 5c) . We next tested whether Jagged2-untransfected DC also activate NK cells in a Notch signaling-dependent manner (Fig. 5d) . NK cells cocultured with CpG-activated DC exhibited increased NK cell cytotoxicity, which was suppressed by GSI treatment (Fig. 5d) . Furthermore, NK cells cocultured with CpG-activated DC up-regulated the Notch target gene, HES1 (Fig. 5e ). Taken together, these studies indicate that Notch signaling, possibly through Jagged2, is crucial for DC-mediated enhancement of NK cell cytotoxicity.
Notch2 Signaling Is Involved in DC-Mediated NK Cell Activation. To identify the receptor that interacts with Jagged2 in our system, we tested the expression of Notch1, Notch2, Notch3, and Notch4 on unstimulated and IL-2-activated NK cells. We detected the expression of Notch1, Notch2, and Notch4 mRNA in unstimulated NK cells by RT-PCR, and we could detect the expression of Notch1-4 after IL-2 stimulation (Fig. 6a) . We could also detect the expression of Notch1 and Notch2 in naïve NK cells by flow cytometry, and their expression was apparently up-regulated by IL-2 stimulation (Fig. 6b) .
We next examined whether ligation of Notch2 increases NK cell activity. NK cells were incubated with anti-Notch2 agonist antibody for 16 h, and NK cell cytotoxic activity against YAC-1 cells was measured. The ligation of Notch2 enhanced NK cell activity, and the treatment of NK cells by GSI inhibited the effect of the anti-Notch2 antibody (Fig. 6c) , indicating that Notch2 is one of the functional receptors for up-regulating NK cell function.
Discussion
Notch signaling controls the development and activation of a variety of immune cells (7, 8, 10, 13, 14) . Recent studies have demonstrated that Jagged and Delta are able to promote the development or activation of NK cells, at least in in vitro culture systems (11, 12, 15) . However, it remains unclear whether Notch signaling controls mature NK cell activation and functional differentiation in vivo, and, if so, it should be important to know which cells affect NK cell activation through the expression of Notch ligands. In this report, we shed light on this issue by demonstrating that stimulation of NK cells with Jagged2 strengthens mature NK cell-killing activity in vivo and in vitro and that Jagged2 expressed on DC plays a crucial role in DC-mediated NK cell activation through interaction with Notch. These findings provide an insight that the modulation of Notch signaling could be a strategy to eradicate tumors or to suppress NK cell-mediated diseases.
Recent studies have provided evidence that NK cells are activated by DC and macrophages (5, 6, (16) (17) (18) (19) , although cellular and molecular mechanisms controlling DC-mediated NK cell cytotoxicity remain unclear. We have addressed this issue by examining whether Notch-signaling plays a crucial role. We observed that Jagged2 expressed on DC is able to enhance NK cell cytotoxic activity through interaction between these cells and that blockade of Notch signaling significantly attenuated the DC-mediated NK cell activation. Furthermore, stimulation of NK cells with an agonist antibody recognizing Notch2 increased NK cell-killing activity. Therefore, these results collectively indicate that Notch signaling is crucial for DC-mediated NK cell activation, possibly through Jagged2 interaction with Notch2. As for the receptor binding Jagged2 on NK cells, we cannot completely rule out the involvement of other Notch receptors, in particular Notch1, because Notch1 is highly expressed on IL-2-activated NK cells. Our present experiments revealed the contribution of Notch signaling in NK activation by using GSI, but GSI affects other signaling pathways (20) . Although our present data also revealed the up-regulation of a Notch-targeted gene in NK cells by DC stimulation, it would be important to confirm the contribution of Notch in NK cell activation by using Notch gene-targeted mice. Additionally, we obtained evidence that Notch signaling directly controls the transcription of granzyme B and perforin in cytotoxic T cells (Y.M. and K.Y., unpublished observation). We also demonstrated in this study that stimulation of NK cells by Jagged2 rapidly up-regulated granzyme B mRNA. These results are in support of the notion that the direct transcriptional activation of cytolytic molecules by Notch signaling could account for the increased effector activity of NK cells. Furthermore, we demonstrated that Jagged2-mediated stimulation of NK cells promotes their proliferation in vitro. Therefore, both up-regulation of effector molecules and increased proliferation of NK cells mediated by Notch signaling would play a major role in strengthening antitumor effects. IL-2 stimulation of NK cells up-regulates Notch1 and Notch2 expression on NK cells. Although a previous report indicated that MyD88-dependent stimulation in DC did not up-regulate Jagged2, evaluated by real-time PCR (9), we observed increased expression of Jagged2 on CpG-stimulated splenic and bone marrow-derived DC by flow cytometry, suggesting that a posttranscriptional mechanism might be involved in this expression. Therefore, TLR9-related infections or autoimmune responses may strengthen Notchmediated NK-DC interactions. In light of recent publications demonstrating the involvement of IL-15 or NKG2D in DCmediated NK cell activation (5, 6) , it is crucial to investigate the unique physiological roles of Notch signaling in DC-mediated NK cell activation in comparison with those by other molecules.
Several previous papers demonstrated that Jagged1, Jagged2, or transient Delta1-mediated signaling stimulate NK cell development (11, 15) , although it remains to be determined which Notch receptors control NK cell development. On the other hand, the present study indicates that Jagged2 directly enhances the cytotoxic activity of mature NK cells, which was inhibited by a ␥-secretase inhibitor, and that the ligation of Notch2 on NK cells augmented NK cell-killing activity. Because Notch 2 is able to bind with Delta1, Delta4, or Jagged1, at least in vitro (21) (data not shown), and CpG-activated DC up-regulate Delta1, Jagged1 and Jagged2, other Notch ligands might be involved in augmenting NK cell activation. However, we think the contribution of Delta1 or Delta4 would be less likely, at least in vivo, because we did not observe an accelerated rejection of tumor cells by transfecting such ligands (data not shown). The evaluation of Jagged1 in DC-NK interactions is currently underway. An intriguing emerging question from these studies is how mature NK cells choose the correct ligand(s) for their activation, because Detla1, Delta4, and Jagged1 as well as Jagged2 are expressed on activated DC (data not shown). One possibility is that the expression pattern or timing of the Notch ligands is limited to particular cells, thus tightly controlling the interaction of NK cells with their correct ligands. Alternatively, the interaction of Notch and Notch ligands might be controlled by modifying the sugar pattern of Notch by fringe genes. The fringe-mediated addition of N-acetylglucosamine to o-fucose moieties on Notch could change the ligand sensitivity of Notch (22) (23) (24) . In support of this, we have observed that NK cells express fringe genes (data not shown). Such modulation of Notch and Notch ligand interaction by fringe may contribute to the selection of the correct ligand(s) for NK cells during their development or activation.
We demonstrated here the possibility that Jagged2 overexpression on DC helps suppress the growth of tumor cells. Because vaccination by DC or by tumor antigen-loaded DC has been widely explored as a method for cancer intervention, the inclusion of Jagged2 in DC-mediated vaccination modalities may prove beneficial because this strategy leads to the activation of NK cells and tumor-specific CD8 ϩ T cells. Furthermore, it might be possible to suppress NK cell-mediated pathogenesis, which is warranted in the context of some autoimmune diseases, by blocking the Jagged2 signaling pathway. Because Notch receptors are widely expressed on a variety of cells, whereas expression of Jagged2 is rather limited, the inhibition of Jagged2 may be preferable to that of other Notch receptors for the purpose of suppressing NK cell activity with fewer side effects.
Materials and Methods
Mice. Six-to 8-wk-old BALB/c and SCID mice were purchased from Japan SLC, and all mice were maintained under specific pathogen-free conditions in the animal research center of the University of Tokushima. All animal studies were approved by the animal research committee of the University of Tokushima.
Transfection, Cell Culture, and Virus Infection. The cDNA of murine Jagged2 was cloned into the pTracer/zeo vector (Fig. S3 ) (Invitrogen) and the pKE004 retroviral vector (8) . Retroviruses were constructed by transfecting vectors into plat-E cells (25) (provided by T. Kitamura, Tokyo University, Tokyo) as reported (24) . After transfection of Jagged2 into A20 or transduction of Jagged2 into YAC-1 or OP9 cells, stable A20, YAC-1, or OP9 cells expressing Jagged2 were maintained. In some experiments, A20 cells were cultured for three days and 1 Ci of 
